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 Introduction 
 Th e value of family history (FH) has been established for assessing 
cardiovascular risk for coronary heart disease, 1 as has its role 
to establish the diagnosis of familial dilated cardiomyopathy 
(FDC). 2,3 However, the sensitivity of FH to detect FDC has been 
infrequently assessed with one earlier estimate of 5%. 4 
 Th e HF-ACTION study provided a recent opportunity to 
further assess the ability of FH to detect FDC. HF-ACTION 
( H eart  F ailure and  A C ontrolled  T rial  I nvestigating  O utcomes 
of Exercise Trai N ing) was a multicenter, prospective, randomized 
clinical trial that aimed to determine whether exercise could 
reduce morbidity and mortality in adult patients with symptomatic 
heart failure and an ejection fraction of 35% or less. 5 
 During the design of the HF-ACTION clinical trial we 
proposed a genetic ancillary study to augment study fi ndings 
and to explore other questions related to dilated cardiomyopathy 
(DCM) and heart failure. Because of our interest in the genetic 
basis of DCM, 6-9 a FH-based study focused on DCM was designed 
and incorporated into the HF-ACTION genetic ancillary. 
 Methods 
 Subject ascertainment 
 Subjects were ascertained from the HF-ACTION study; its entry 
criteria included patients with a left  ventricular ejection fraction 
<35% and New York Heart Class II–IV heart failure on optimal 
medical therapy. 5 A total of 2,331 patients were enrolled at 82 
centers in the United States, Canada, and France. 10 All patients 
participating in the HF-ACTION trial at sites with IRB approval 
for a genetic ancillary study were eligible for enrollment, which 
included providing a peripheral blood sample that would be 
used to prepare DNA for storage and later use. A component 
of the genetic ancillary was a FH study, which was based at the 
Oregon Health & Science University (OHSU) with the principal 
investigator (REH). Patients who were recruited to the genetic 
ancillary study were also asked if they wished to participate in 
the FH study, which included providing contact information to 
study personnel at OHSU and completing mailed questionnaires 
regarding personal medical and FH. 
 Subject consent 
 The genetic ancillary and FH study was approved by the 
Institutional Review Board at OHSU and at each of the other 
participating sites. Signed informed consent was obtained from 
all individuals participating in the genetic ancillary and the FH 
study at each of the individual’s respective enrolling center. 
 Data and sample collection 
 For those individuals who enrolled in the FH study, the enrolling 
HF-ACTION site’s study team, who had available clinical 
data to characterize the heart failure phenotype, adjudicated 
whether the subject had ischemic or nonischemic disease. A 
member of the research team at each HF-ACTION participating 
site communicated via a standardized fax form (Supporting 
Information Data S1) that was transmitted to OHSU for 
participating patients. Th e faxed information included the study 
participant’s contact information and their cause of heart failure 
(ischemic or nonischemic), and if nonischemic, whether the cause 
was known, and if so, whether it was attributed to idiopathic, valvular, 
hypertension, alcohol, radiation, or some other cause (Data S1). 
Consenting patients were then sent one of two questionnaires 
based on the data received from the site at which they were enrolled. 
Patients reported to be ischemic were sent the fi rst six pages of a 
questionnaire that asked for basic demographic information and 
questions specifi c to ischemic disease (heart attack, bypass surgery, 
 Family History of Dilated Cardiomyopathy among Patients with Heart 
Failure from the HF-ACTION Genetic Ancillary Study 
 Laura  Hudson ,  M.A. M.P.H. 1 ,  Ana  Morales ,  M.S., C.G.C. 2 ,  Ana Clara  Mauro ,  M.P.H. 1 ,  David  Whellan ,  M.D. M.P.H. 3 ,  Kirkwood F.  Adams , 
 M.D. 4 ,  Christopher M.  O’Connor ,  M.D. 5 ,  and  Ray E.  Hershberger ,  M.D. 2 
 Articles 
 1 University of Miami Miller School of Medicine ,  Miami ,  Florida ,  USA ;  2 The Ohio State University College of Medicine, Columbus, Ohio, USA ;  3 Jefferson Medical College ,  Philadelphia , 
 Pennsylvania ,  USA ;  4 University of North Carolina at Chapel Hill ,  Chapel Hill ,  North Carolina ,  USA ;  5 Duke University and the Duke Clinical Research Institute ,  Durham ,  North Carolina ,  USA . 
 Correspondence: Ray E. Hershberger (Ray.Hershberger@osumc.edu)
 DOI: 10.1111/cts.12041 
WWW.CTSJOURNAL.COM 179VOLUME 6 • ISSUE 3
 Abstract 
 Background:  The value of family history (FH) is well established, but its sensitivity to detect familial dilated cardiomyopathy (FDC) 
has been infrequently examined. 
 Methods:  A genetic ancillary study was created as a component of the HF-ACTION trial, a multicenter, prospective, randomized clinical 
trial of exercise in patients with heart failure and an ejection fraction <35%. A FH-based study using a structured questionnaire mailed 
to all consenting individuals was incorporated into the genetic ancillary. FH responses were analyzed for dilated cardiomyopathy (DCM) 
in family members. 
 Results:  Of the 741 individuals with data available, 358 (48.3%) had nonischemic and 383 (51.6%) had ischemic etiology, and of 
these 164 (45.8%) and 201 (52.4%), respectively, returned evaluable questionnaires. Of those with nonischemic etiology, 14/164 
(8.5%) reported at least one fi rst-degree family member with DCM or an enlarged heart; another 21/164 (12.8%) reported a FH of 
“cardiomyopathy,” a less specifi c term to indicate DCM. 
 Conclusion:  At least 8.5% of patients with nonischemic etiology in the HF-ACTION genetic ancillary study provided FH indicating 
familial DCM, information important to inform further genetic analyses of this cohort and to plan other studies. Clin Trans Sci 2013; 
Volume 6: 179–183 
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angioplasty/stent, coronary artery disease, angina, blocked 
arteries per cardiac catheterization) to confi rm their ischemic 
diagnosis (Supporting Information Data S2). Patients with 
reported nonischemic disease were sent the full questionnaire that 
included the fi rst six pages and an additional six pages containing 
a more extensive set of questions designed to gather information 
regarding the cause of their cardiomyopathy and heart failure 
(Supporting Information Data S3). Both questionnaires (ischemic 
and nonischemic) contained a detailed family medical history 
questionnaire. Participants were asked to return the questionnaire to 
OHSU by mail. Nonresponders were sent up to 3 reminder postcards 
at 1–2-month intervals soliciting questionnaire completion and 
return. Completed questionnaires received from study participants 
were fi led in locked cabinets that were subsequently transported 
to the University of Miami and then to the Ohio State University 
upon relocation of study operations. Th e research team at the 
University of Miami entered all available questionnaire data, 
including pedigrees and all FH data, into Progeny (Delray Beach, 
FL, USA), a database designed for family based genetic research in 
use by the FDC Research Project. 6 Data entry was verifi ed by study 
personnel and stored in the Progeny database. 
 Data analysis 
 A database query was conducted to collect the following FH 
information from each family member reported in the FH: cause 
of death, history of heart problems, type of heart problems, 
and other health history. All of the information reported was 
qualitatively analyzed and assigned eight possible categories 
(Table  1 ). Th e categories were ranked by relevance with the highest 
rank category taking precedence for analysis. Aft er analyzing the 
medical history of all reported family members, the same rubric 
was applied to the entire family. For example, if an individual 
categorized as having heart disease had a relative with a “weak 
heart” (cardiomyopathy, rank 2, Table  1 ), the FH was categorized as 
positive for cardiomyopathy. All FH assignments were adjudicated 
by a genetic counselor (AM) with prior DCM research training 
and experience 3,8 and those ranked in categories 1 and 2 were 
reviewed by the study principal investigator (REH). 
 Results 
 Demographics 
 A total of 766 individuals from 38 study centers consented to the 
overall genetic ancillary and provided consent for participation 
in the OHSU family history study, of which 741 of the 766 
(96.7%) had data available that allowed for adjudication of 
ischemic or nonischemic etiology; 383 (51.7%) were ischemic 
and 358 (48.3%) were nonischemic (Table  2 ). Of the patients 
who consented to the OHSU family history study, 383 of the 
741 (50.0%) returned medical and FH questionnaires, and of 
these 383, 164 (45.8%) and 201 (52.4%) were from nonischemic 
and ischemic etiology, respectively. Th e average age of those 
with ischemic disease was approximately 10 years older than 
the nonischemic group (Table  2 ). 
 Clinical characteristics 
 Selected clinical characteristics from those with nonischemic 
etiology provide insight into this study cohort (Table  3 ). 
Symptoms leading to heart failure were conventional. Most 
patients had undergone coronary angiography, indicating that 
their assignment to a nonischemic category had been validated. 
 Rank History Descriptors 
1 Dilated 
 cardiomyopathy 
Dilated cardiomyopathy, enlarged heart 
2 Cardiomyopathy Weak heart, damage to heart muscle 
3 Heart failure Heart failure, congestive heart failure 
4 Heart disease Heart problems, heart related, heart 
blockage, angina, blocked arteries, 
broken heart, heart attack, valvular 
disease, sudden cardiac death, coronary 
artery disease, cardiac arrest/cessation, 
arrhythmia, slow beat, fast beat, beat 
problems, atrial fi brillation, hole in 
heart, mural thrombus, angina 
5 Cardiovascular 
disease, other 
Hypertension, hypotension, stroke, 




“Died in sleep,” “died suddenly,” 
“stopped breathing,” dropped 
dead, seizure, other miscellaneous 
cardiovascular-related items that raise 
suspicion of cardiac etiology 
7 Other Cancer, noncardiovascular related 
accident, renal disease, infection 
8 Unable to 
assess 
Illegible entries, old age, natural 
causes, left blank 
9 None Explicitly stated “none” 
 Table 1.  Family history categories. 
 Total Ischemic Nonisch-
emic 
Consented to family 
history study 
766 383 358 
Gender 
 Males 516 297 204 
 Females 247 86 151 
 Unknown or no data 3 0 3 
Age 
  Male and female, 
(mean, median, 







  Males (mean, 







  Females (mean, 








 White 274 162 106 
 Black 84 26 55 
 Native American 20 14 6 
 Asian 4 3 1 
 Pacifi c Islander 1 1 0 
 Unknown 1 383 177 190 
 1In most cases race was unknown because questionnaires were not returned. 
 Table 2.  Participant demographics. 
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Substance abuse was minimal consistent with recruitment of a 
selected population for a clinical trial. 
 Study site coordinator diagnostic assignments 
 Study site coordinator etiologic assignments were congruent with 
diagnoses from the medical history questionnaires in all cases 
except one patient with nonischemic disease (Table  4 ). By study 
site coordinator data, most patients with ischemic etiology had 
a myocardial infarction, coronary artery bypass graft ing, or a 
percutaneous coronary intervention, confi rming their ischemic 
etiology, and all had information supporting of ischemic etiology 
noted on the medical history questionnaires. 
 The nonischemic group contained a variety of study 
coordinator assigned causes (Table  4 ). In only one case did the 
study site coordinator assignment (IDC) vary from that of the 
patient’s medical history (coronary artery disease), although it is 
also possible that the patient may have developed coronary artery 
disease aft er the IDC diagnosis. 
 Family history 
 Participants with nonischemic disease reported 1,019 fi rst-degree, 
1,245 second-degree, and 5 third-degree relatives. Participants 
with ischemic disease reported 1,317 fi rst-degree, 349 second-
degree, and 14 third-degree relatives. 
 Of the 358 probands with nonischemic etiology, 14 of the 
164 with evaluable questionnaires (8.5%) reported at least 
one family member with DCM (Table  5 ). To describe their 
family history of DCM, respondents used the terms “dilated 
cardiomyopathy” ( n = 1) or “enlarged heart” ( n = 21), the latter 
term considered as a surrogate lay term for DCM. Of these 22 
relatives, 15 were fi rst-degree, 6 were second-degree and one 
was a third-degree relative. 
 Twenty-one other respondents of the 164 with evaluable 
questionnaires in the nonischemic group (12.8%) indicated they 
had a FH of “cardiomyopathy” (Table  5 ), which was considered 
less specifi c for DCM than “dilated cardiomyopathy” or “enlarged 
heart,” although this terminology may well have represented DCM 
in some cases. 
 We also tabulated progressively more general terms refl ecting 
cardiovascular disease in the family histories of those respondents 
of the nonischemic group. Th ese terms included “heart failure,” 
reported in the family histories of 34, or an even more generic 
term “heart disease” in 75 (Table  5 ). Again, because of the limited 
study design we were unable to obtain medical records of family 
members to validate these family histories. 
 Among the 383 participants with ischemic heart disease for 
whom FH information was available, 8 reported at least one other 
relative with DCM, only 2 reported a FH of cardiomyopathy 
(type not specifi ed), fewer than those in the nonischemic group 
(Table  5 ). However, 47 and 115 reported a FH of heart failure or 
heart disease, more than the nonischemic respondents. 
  N % of total 
 Symptoms leading to diagnosis 
 Fatigue 115 70.1% 
 Shortness of breath 108 65.9% 
 Dyspnea on exertion 108 65.9% 
 Orthopnea 79 48.2% 
 Paroxysmal nocturnal dyspnea 77 47.0% 
 Edema 71 43.3% 
 Irregular heart beat, palpitations 69 42.1% 
 Weight loss or gain 52 31.7% 
 Dizziness, fainting, loss of consciousness 51 31.1% 
 Flu-like symptoms 49 29.9% 
 Chest pain 47 28.7% 
 Tests and procedures 
 Echocardiogram 158 96.3% 
 ECG 158 96.3% 
 Coronary angiogram 138 84.1% 
 Pacemaker 57 34.8% 
 Implantable cardiac defi brillator 54 32.9% 
 Ventricular assist device 8 4.9% 
 Heart transplant 1 0.6% 
 Pertinent social history 
 Alcohol (past) 68 41.5% 
 Alcohol (current) 51 31.1% 
 Cigarettes (past) 66 40.2% 
 Cigarettes (current) 17 10.4% 
 Recreational drugs history 11 6.7% 
 Table 3.  Clinical characteristics from questionnaires of 164 patients with nonischemic 
cardiomyopathy. 
 Total 
 Ischemic cardiomyopathy 383 
 Coronary artery bypass surgery 194 
 Received one or more coronary stents 156 
 Myocardial infarction 297 
 Nonischemic cardiomyopathy 358 
 IDC 159 
  Negative coronary angiogram 107 
  FDC 2 
  PPCM 8 
 Valvular 13 
  Mitral valve replacement 6 
  Aortic valve replacement 6 
  Not specifi ed 2 
 Hypertension 51 
 Alcoholic 2 
 Adriamycin 6 
 Radiation 1 
 Other 1 21 
 Not specifi ed 105 
 1Myocarditis/viral ( n = 12), rheumatic fever ( n = 2), arrhythmia/cardiac arrest ( n = 1), 
lupus ( n = 1), muscular dystrophy ( n = 1), nonobstructive coronary artery disease 
( n = 1), sarcoid ( n = 1), thrombocytopenic purpura ( n = 1), obesity ( n = 1). 
 Table 4.  Study site coordinator assignments. 
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 Discussion 
 This OHSU Family History study was undertaken as a 
component of the HF-ACTION genetic ancillary in an eff ort 
to detect FDC diagnoses in those HF-ACTION participants 
who had nonischemic DCM as an etiology. Th e study utilized 
a comprehensive medical and FH questionnaire that was sent 
to consenting individuals. Th e questionnaire was designed to 
accomplish two objectives: to validate nonischemic or ischemic 
diagnoses provided by the HF-ACTION site personnel where an 
individual was recruited, and to determine if familial DCM was 
present from FH. We note that, to our knowledge, this is the fi rst 
study to attempt to defi ne the frequency of familial DCM in an 
NHLBI-sponsored cardiovascular clinical trial. 
 Th e fi rst objective was attained, as the questionnaire data from 
patients agreed with site personnel diagnoses in all cases except 
one, in which nonischemic cause by site personnel was reported 
while the patient questionnaire indicated ischemic disease. 
However, it is possible that the ischemic disease occurred aft er 
the diagnosis of nonischemic disease. Th e second objective was 
also attained, as a family history of cardiomyopathy was identifi ed 
in some patients with nonischemic diagnoses, and of the 164 
who returned questionnaires, the frequency of familial DCM was 
reported by 14, or 8.5% of the cohort who returned questionnaires. 
 Of the 358 assigned as nonischemic by study coordinators 
(Table   4 ), 159 (44%) were assigned as IDC, of which 2 had 
FDC and 8 were indicated to have peripartum cardiomyopathy. 
Th is estimate of IDC as a fraction of those with nonischemic 
cardiomyopathy appears low when compared to the Beta-
Blocker Evaluation of Survival Trial (BEST), another NIH-
supported heart failure trial, that assigned IDC to 379 of 563 
(67.3%) with nonischemic etiology. 11 However, in our study 105 
had no etiologic assignment provided beyond classifying into 
the “nonischemic” category, which may explain this diff erence. 
Further, 94 had a variety of other diagnoses assigned (valvular, 
hypertension, alcohol, adriamycin, radiation and others) beyond 
that of nonischemic cardiomyopathy. While a consensus has 
emerged that FDC has a genetic basis, whether IDC shares a 
similar genetic basis remains uncertain. Further, whether any of 
these subcategories of nonischemic cardiomyopathy may have a 
rare variant genetic background, similar to FDC or IDC, remains 
unknown but now becomes a testable hypothesis. 
 Th is information is valuable because it will help to inform 
genetic analyses of the DNA specimens collected from these 
individuals who participated in the HF-ACTION genetic ancillary 
study, especially for studies that may be undertaken to evaluate 
a genetic basis of the nonischemic cardiomyopathies of the 358 
individuals so categorized. Th e HF-ACTION genetic ancillary 
study was a multisite NHLBI-sponsored heart failure study that 
recruited from a very broad geographic area of North America 
with participants from 38 sites in North America, which may be 
particularly helpful to generalize any results from genetic studies 
to the larger heart failure population. 
 It has been well established that FH is less sensitive than the 
clinical screening of fi rst-degree family members by history, exam, 
echocardiography and ECG, 2,9 with one study showing that only 5% 
of FDC was detected by family history while 20% was detected by 
clinical screening of family members. 4 Th is information suggests 
that the estimate of FDC ranging up to 12.5% suggested in this 
study may be plausible, and that to identify the true fraction of 
patients whose family members have DCM, family members must 
undergo clinical screening (echocardiogram, ECG), procedures 
that exceeded the scope of this study. 
 Limitations 
 None of the diagnoses provided by the index patients (i.e., the HF-
ACTION participants) for their family members and attributed 
as DCM were validated by review of the family members’ medical 
records. Nevertheless, all of these patients were recruited at 
medical centers that provided information about the family 
study, its background and its goals, including information that 
DCM may run in families, and most patients with nonischemic 
cardiomyopathy, as inferred from their questionnaire responses 
that showed almost universal concordance with their coordinator-
specified diagnosis, understood that their DCM was not a 
consequence of coronary artery disease, which increases the 
likelihood that the DCM they reported in their relatives correctly 
assigned ischemic or nonischemic etiology. We presume that the 
164 who returned questionnaires were a representative sample of 
the 358 in the nonischemic group, although it is possible that those 
with a positive family history of DCM may have preferentially 
participated in this study. Even so, the most conservative estimate 
of familial DCM would be 14 of 358, or 3.9%. 
 Conclusion 
 Th is family history study, a component of the HF-ACTION genetic 
ancillary, suggested that at least 8.5% of patients with nonischemic 
DCM had family history consistent with familial DCM. 
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 Supporting Information. 
 Additional Supporting Information may be found in the online 
version of this paper: 
 Nonischemic Ischemic 
Total number 358 383 
Number of 




returned or no data 
194 182 
Data components 1  N (% of total; % 
of questionnaires 
assessed) 
 N (% of total; % 
of questionnaires 
assessed) 
  Dilated 
 cardiomyopathy 
14 (3.9%; 8.5%) 8 (2.1%; 4.0%) 
 Cardiomyopathy 21 (5.9%; 12.8%) 2 (0.5%; 1.0%) 
 Heart failure 34 (9.5%; 20.7%) 47 (12.3%; 23.4%) 
 Heart disease 75 (20.9%; 45.7%) 115 (30%; 57.2%) 
  Cardiovascular 
disease, other 
5 (1.4%; 3.0%) 14 (3.7%; 7%) 
  Suspected 
 cardiovascular disease 
1 (0.3%; 0.6%) 1 (0.3%; 0.5%) 
 Other 9 (2.5%; 5.5%) 12 (3.1%; 6%) 
 None 5 (1.4%; 3.0%) 2 (0.1%; 1%) 
 1Data components from family history questionnaires as described in Table  1 . 
 Table 5.  Family history questionnaires. 
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Data S1. Standardized fax form.
Data S2. Th e Genetic Basis of Dilated Cardiomyopathy Study 
(GDC Study), Screening Questionnaire.
Data S3. Th e Genetic Basis of Dilated Cardiomyopathy Study 
(GDC Study), Comprehensive Questionnaire.
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